A recent study reveals that some prostate cancer survivors have a persistent fear of cancer recurrence (FCR) even many years after diagnosis and treatment.
Level of education, years since prostate removal, signs of cancer recurrence, and current therapies were predictors of FCR. The findings are published by Wiley early online in CANCER, a peer-reviewed journal of the American Cancer Society.
The study included 2,417 survivors of prostate removal who completed a questionnaire (on average) seven years after surgery, with another questionnaire completed nine years later.
Responses revealed that 6.5% and 8.4% of patients reported high FCR at the initial assessment and at follow-up, respectively.
High FCR at the initial assessment was the strongest predictor of having FCR nine years later. Other predictors of FCR at the follow-up assessment included:
- lower level of education,
- more years since prostate cancer surgery,
- signs of cancer recurrence in the first years after treatment,
- current receipt of therapy for prostate cancer, and anxiety.
“Since FCR remains a burden to certain prostate cancer survivors even many years after their diagnosis and treatment, health care professionals should monitor for it to identify patients at risk and provide appropriate psychosocial care because FCR is leading to limitations in quality of life and psychological well‐being,” said lead author Valentin Meissner, MD, of The Technical University of Munich, in Germany.
An accompanying editorial notes that “this study is the largest registry study to date on the longest longitudinal analysis of FCR.” The editorial’s authors describe additional research that should be conducted related to FCR.
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.